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MALT1 is a central signaling component in innate and adaptive immunity by regulating
NF-κB and other key signaling pathways in different cell types. Activities of MALT1
are mediated by its scaffold and protease functions. Because of its role in lymphocyte
activation and proliferation, inhibition of MALT1 proteolytic activity is of high interest for
therapeutic targeting in autoimmunity and certain lymphomas. However, recent studies
showing that Malt1 protease-dead knock-in (Malt1-PD) mice suffer from autoimmune
disease have somewhat tempered the initial enthusiasm. Although it has been proposed
that an imbalance between immune suppressive regulatory T cells (Tregs) and activated
effector CD4+ T cells plays a key role in the autoimmune phenotype of Malt1-PD mice,
the specific contribution of MALT1 proteolytic activity in T cells remains unclear. Using
T cell-conditionalMalt1 protease-dead knock-in (Malt1-PDT) mice, we here demonstrate
that MALT1 has a T cell-intrinsic role in regulating the homeostasis and function of thymic
and peripheral T cells. T cell-specific ablation of MALT1 proteolytic activity phenocopies
mice in which MALT1 proteolytic activity has been genetically inactivated in all cell types.
The Malt1-PDT mice have a reduced number of Tregs in the thymus and periphery,
although the effect in the periphery is less pronounced compared to full-body Malt1-PD
mice, indicating that also other cell types may promote Treg induction in a MALT1
protease-dependent manner. Despite the difference in peripheral Treg number, both
T cell-specific and full-bodyMalt1-PD mice develop ataxia and multi-organ inflammation
to a similar extent. Furthermore, reconstitution of the full-body Malt1-PD mice with
T cell-specific expression of wild-type humanMALT1 eliminated all signs of autoimmunity.
Together, these findings establish an important T cell-intrinsic role of MALT1 proteolytic
activity in the suppression of autoimmune responses.
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INTRODUCTION
MALT1 (PCASP1 or paracaspase-1) is ubiquitously expressed in multiple cell types, where it
is involved in signaling leading to pro-inflammatory gene expression. The best known role of
MALT1 is the activation of NF-κB signaling in response to T cell and B cell antigen receptor
triggering, which is critical for the adaptive immune system. At the border between the innate
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and adaptive immune system, MALT1 acts downstream of
several innate immune receptors on antigen-presenting dendritic
cells (DC), which in turn regulate cytokine production that
can influence the polarization of the adaptive immune system.
MALT1 is also critical for NF-κB induction, but not for
degranulation responses, downstream of several ITAM-coupled
natural killer cell (NK) receptors and the Fcε receptor on mast
cells (1). MALT1-deficient mice and patients show primary
immunodeficiency (PID) via defects in T and B cells, in
particular marginal zone (MZ) B cell development and antigen-
induced T cell proliferation and activation, which leads to
immunodeficiency and failure to respond to vaccination (2–8).
A MALT1-deficient patient suffering from recurrent infections
was cured by transplantation of mostly T cells (8). This indicates
a major role for T cells as a determinant of the compromised
immunity phenotypes caused by MALT1 deficiency. T cells are
highly dependent on antigen receptor signaling, which requires
MALT1. In contrast, B cells can be alternatively activated by
innate receptors in a MALT1-independent manner. This might
explain the lower phenotypic impact of MALT1 deficiency in
B cells (2, 6, 7, 9). MALT1 signaling in non-lymphoid cells is
also critical for optimal immunity, as illustrated by PID patients
susceptible to fungal infections due to a CARD9 mutant that
fails to recruit downstream BCL10 and MALT1 (10). Apart
from its role in immune signaling through loss-of-function,
aberrant activation or expression of MALT1 has been associated
to different forms of B cell cancer, such as ABC-DLBCL (11–
14), low-grade MALT lymphomas (15–19), and a complex type
of PID called B cell expansion with NF-κB and T cell anergy
(BENTA) (20, 21).
MALT1 belongs to the type 1 paracaspase family, an ancient
protein family that originated before the last common ancestor
of planulozoa (bilaterians and cnidarians) (22, 23). The type
1 paracaspases consist of an amino-terminal death domain,
immunoglobulin domains and a caspase-like domain. Upon
activation, MALT1 acts as a scaffold and recruits critical
downstream signaling components such as TRAF6 and TAK1 in
order to activate NF-κB and JNK/AP-1 dependent transcription
(2, 3, 24, 25). The caspase-like domain has received plenty of
research attention after it was established that paracaspases have
protease activity (26, 27). Both the scaffold function leading
to NF-κB and the protease activity of MALT1 are of critical
importance, since they have been functionally conserved at least
as far back as the last common ancestor of the three type
1 paracaspase paralogs in jawed vertebrates (22, 23). An ever
growing list of paracaspase protease substrates—which at this
moment includes auto-processing (28–30), adaptor proteins (27),
transcription factors (31), deubiquitinases (26, 32), ubiquitin
ligases (33–35) and specific RNA degrading enzymes (36–38)—
illustrate that MALT1 protease activity removes inhibitory
proteins and fine-tunes the type of responses that are induced
(1, 39). There is only a single member of the paracaspase
family in mammals (22). This, as well as the signal fine-tuning
by an enzymatic activity, makes MALT1 protease activity a
very attractive therapeutic target in humans for the treatment
of autoimmunity and some cancers. At this moment, several
independent studies have described active site or allosteric
MALT1 protease inhibitors (11–14, 40–45), and mouse studies
have already indicated the therapeutic value of some of these
inhibitors in certain types of cancer (13, 14, 43, 46) and
inflammatory diseases (40). Recently, four independent papers
reported unexpected autoimmune phenotypes such as multi-
organ inflammation, including the stomach, and ataxia in
full-body Malt1-PD mice (4–6, 47), which could indicate a
risk when inhibiting MALT1 protease activity for therapeutic
reasons. While at first sight counter-intuitive, autoimmune
or autoinflammatory diseases (AID) are in fact common in
patients suffering from PID (48). The general conclusion from
the different Malt1-PD mouse studies was that the disease
was caused by an imbalance between effector CD4+ T cells
and Tregs (4, 5). Much of the disease could be mitigated
by deletion of IFN-γ in the Malt1-PD mice, indicating that
IFN-γ is a primary driver of disease (5). However, another
report also suggested a contribution from immune-regulatory
IL-10 producing B-cells (Bregs) (47). Moreover, MALT1 also
regulates the activation of DC cells, NK cells and mast cells (1),
indicating the possibility that MALT1 activity in some of these
cells may also regulate inflammatory T and B cell responses
associated with autoimmunity in Malt1-PD mice. Given the
complexity of MALT1 function in the development of lymphoid
cells and activation of several immune cells, the study of cell-
intrinsic functions of MALT1 requiresMalt1 conditional knock-
in (KI) mice. In order to better predict safety risks upon
pharmacological MALT1 protease inhibition and get further
insight into the role of T cells in the autoimmune pathology
of Malt1-PD mice, we employed conditional KI mice lacking
MALT1 proteolytic activity specifically in T cells (Malt1-PDT),
and compared their phenotype with mice lacking MALT1
proteolytic activity in all cell types (Malt1-PD). To verify that
only MALT1 protease deficiency in T cells can cause the disease,
we also reconstituted Malt1-PD mice with transgenic T cell-
specific expression of human wild-type (WT) MALT1. Taken
together, we show that T cell-specific inactivation of MALT1
proteolytic activity phenocopies inactivation of MALT1 in all cell
types, resulting in a disruption in T cell immune homeostasis and
development of autoimmunity, indicating an important T cell-
intrinsic role of MALT1 proteolytic activity in keeping normal
immune homeostasis.
RESULTS
T Cell-Specific Loss of MALT1 Proteolytic
Activity Is Sufficient to Cause Ataxia and
Weight Retardation to the Same Extent as
Full-Body Loss of MALT1 Proteolytic
Activity
To characterize the contribution of hematopoietic cells in the
autoimmune phenotype of Malt1-PD mice, all previous studies
have relied on crosses with other knock-out (KO) lines (e.g.,
IFN-γ KO), bone marrow transplants and injection of WT
Tregs (4–6, 47). However, none of these experiments allow
an undeniable conclusion on the specific role of T cells in
the different autoimmune responses observed in Malt1-PD
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FIGURE 1 | Malt1-PD and Malt1-PDT mice display ataxia and weight
retardation. (A,B) Representative pictures of Malt1-PD and -PDT mice
suffering from ataxia, characterized by leg clutching. (C) Ataxia onset in male
and female control, Malt1-PD and -PDT mice monitored from week 8 to 15
(male mice: control n = 41, Malt1-PD n = 16, and Malt1-PDT n = 8;
(Continued)
FIGURE 1 | female mice: control n = 37, Malt1-PD n = 26 and Malt1-PDT
n = 7). (D) Weight retardation in male and female Malt1-PD and -PDT mice
monitored from week 8-12 until termination. Values after week 12 are excluded
due to a too low number of surviving Malt1-PDT mice, causing very broad
95% confidence intervals. Male mice: week 8: control n = 41, Malt1-PD n = 9
and Malt1-PDT n = 6; week 9: control n = 49, Malt1-PD n = 8 and
Malt1-PDT n = 8; week 10: control n = 50, Malt1-PD n = 11 and Malt1-PDT
n = 7; week 11: control n = 61, Malt1-PD n = 16 and Malt1-PDT n = 8; week
12: control n = 59, Malt1-PD n = 16 and Malt1-PDT n = 7 and female mice:
week 8: control n = 37, Malt1-PD n = 10 and Malt1-PDT n = 3; week 9:
control n = 49, Malt1-PD n = 18 and Malt1-PDT n = 6; week 10: control n =
50, Malt1-PD n = 23 and Malt1-PDT n = 5; week 11: control n = 56,
Malt1-PD n = 27 and Malt1-PDT n = 6; week 12: control n = 54, Malt1-PD
n = 26 and Malt1-PDT n = 6.
mice. In order to further characterize this phenotype, we
generated T cell-specific Malt1-PDT mice and compared their
phenotype with that of full-body Malt1-PD mice that we also
generated. We used the F1 offspring from the Malt1FL/FL
CD4-Cre X Malt1PD/+ cross, where the Malt1PD/FL CD4-Cre
offspring representMalt1-PDTmice. The remaining F1 offspring
(Malt1PD/FL, Malt1+/FL, and Malt+/FL CD4-Cre) all behaved
as WT and were consequently all used as phenotypic controls
(Supplemental Figures 1A–C). To obtain a positive phenotypic
control, Malt1PD/+ were crossed with Malt1−LacZ/−LacZ KO
mice, where Malt1PD/−LacZ F1 offspring represent full-body
Malt1-PD mice and Malt1+/−LacZ offspring represent healthy
controls with the same gene dosage as our Malt1-PDT mice
(Supplemental Figures 1A–C). Just like in the full-body Malt1-
PD mice, the T cell-specific Malt1-PDT mice displayed a weight
retardation, starting from approximately 9 weeks of age, and
ataxia, starting on average at 11–12 weeks of age (Figures 1A–D).
This is also similar to what was previously observed for other full-
body Malt1-PD mice in several independent studies (4–6, 47).
A WT mouse will stretch its hind legs when suspended by its
tail to maintain its balance (Figure 1A). A mouse suffering from
ataxia will flail around with its hind legs at an early stage of
disease and start clutching its hind paws (and sometimes also
front paws) at a more advanced stage (Figures 1A,B). We scored
a mouse as having ataxia at the moment the hind paws were
completely clutched while hanging by the tail. Although time
of onset was not different (Figures 1C,D), we noticed that the
overall symptoms were more severe in females than in males,
which is similar to what has been previously observed in an
independent Malt1-PD mouse line (47). This observation is also
consistent with the sexual dimorphism in autoimmune diseases
seen in humans (49, 50). Since the T cell-specificMalt1-PDTmice
show as severe disease development as the full-body Malt1-PD
mice, we can conclude that absence of MALT1 protease activity
in T cells only is sufficient to induce ataxia and weight loss to a
similar extent as induced by its absence in all body cells.
T Cell-Specific Loss of MALT1 Proteolytic
Activity Causes Multi-Organ Inflammation
After birth, mice were checked regularly and no external signs
of suffering could be observed before the development of
ataxia. However, upon sacrifice we noticed that the stomach
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FIGURE 2 | Multi-organ inflammation in Malt1-PD and Malt1-PDT mice. (A,B) Representative pictures of stomach of Malt1-PD and -PDT mice with increased
vascularization compared to their corresponding controls. (C,D) H&E staining showing immune infiltration in the submucosa of the stomach of Malt1-PD (C) and
Malt1-PDT (D) mice. Scale bar 100µm. (E,F) H&E staining showing immune infiltration in the salivary gland of Malt1-PD (E) and Malt1-PDT (F) mice. Scale bar
100µm. (G,H) H&E staining showing immune infiltration in the lacrimal gland of Malt1-PD (G) and Malt1-PDT (H) mice. Scale bar 100µm.
of Malt1-PD and -PDT mice was more rigid and vascularised
(Figures 2A,B). By means of H&E staining we also observed
severe gastritis, plus immune infiltration in lacrimal and
salivary glands indicating that the mice already had developed
inflammation in other organs (Figures 2C–H). In order to
minimize the suffering of mice, we euthanized them as soon
as possible after the observation of ataxia. To assess whether
disease development inMalt1-PD and -PDT mice was due to the
same mechanism, we evaluated cytokine production by CD44+
CD4+ T cells in cervical lymph nodes (cLN) of mice already
suffering from ataxia. We decided to analyze cLN as they are
located close to known inflamed organs. Both Malt1-PD and -
PDT mice have a slight reduction in total CD4+ T cells and an
increase in CD4+ T cells that express CD44, so-called effector
CD4+ T cells compared to WT control mice (Figures 3A,B).
We also observed a strong upregulation of IFN-γ-producing
CD44+CD4+ T cells in Malt1-PD and -PDT mice, indicating a
T cell intrinsic role for MALT1 protease activity in restricting
Th1 responses (Figure 3C). We further assessed serum cytokine
levels in Malt1-PD and -PDT mice. For IL-2 and TNF there was
a significant, but mild increase in the Malt1-PD compared to
control mice, which was no longer detectable inMalt1-PDTmice.
No increase in IL-4, IL-6, IL-17 and IFN-γ could be detected
in serum of Malt1-PD and -PDT mice (Figure 3D). Therefore,
we can conclude that both Malt1-PD and -PDT mice do not
suffer from systemic inflammation, but instead suffer from local
Th1-associated multi-organ inflammation.
A T Cell-Intrinsic Role for MALT1
Proteolytic Activity Is Critical for Thymic
nTreg Development
The best known Tregs are Foxp3+CD25+CD4+ T cells
(51), which have two distinct developmental origins. Some
develop in the thymus at a young age—the so-called natural
Tregs (nTregs). Others mature in the periphery from naïve
conventional T cells during extended exposure to antigen or
under inflammatory conditions—the so-called induced Tregs
(iTregs). Both populations are genetically distinct and have
non-redundant functions (52, 53). MALT1 has been shown
to be specifically required for thymic Treg development,
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FIGURE 3 | Inflammation in Malt1-PD and Malt1-PDT mice is local and not systemic. (A) CD4+ T cells in Malt1-PD (top panel) and Malt1-PDT (bottom panel) mice.
(B) CD44+CD4+ T cells in Malt1-PD (top panel) and Malt1-PDT (bottom panel) mice. (C) CD44+CD4+ T cells producing IFN-γ in Malt1-PD (top panel) and
Malt1-PDT (bottom panel) mice. For (A–C) lymphocytes from cLN were stimulated for 4 h with PMA/ionomycin and brefeldin A to determine the different cell
populations by flow cytometry. Malt1-PD mice: n = 11, corresponding control mice: n = 12; Malt1-PDT mice: n = 6, corresponding control mice: n = 9. (D) Serum
levels of IL-2, IL-4, IL-6, IL-17, IFN-γ, and TNF in Malt1-PD (top panels) and Malt1-PDT (bottom panels) mice. Data represent three separate serum collections:
collection 1 = filled squares, collection 2 = open squares and collection 3 = open circles. Malt1-PD mice: n = 10, corresponding control mice: n = 11 and Malt1-PDT
mice: n = 11, corresponding control mice: n = 10. The mean ± SEM is indicated on the graphs. The statistical significance between groups was calculated with an
unpaired 2 tailed Student’s t-test: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
while induced peripheral Treg formation in aged mice is not
inhibited by MALT1 deficiency (4, 5, 54). The ability to induce
Treg formation in Malt1-KO mice is also consistent with
previous in vitro differentiation studies using a high dose of
anti-CD3 to stimulate the TCR (55). This might indicate a
threshold effect which is influenced by MALT1. Therefore, we
investigated the role of MALT1 proteolytic activity in thymic
Treg development in young healthy (ataxia-free) Malt1-PD
and -PDT mice. A clear defect in thymic Treg development
could be observed, since Foxp3+CD25+CD4+ T cells were
almost absent in the thymus of young Malt1-PD and -PDT
mice (Figures 4A,B). Furthermore, thymic Treg development
could be rescued upon transgenic expression of human WT
MALT1 in cells targeted by CD4-Cre (Figures 4D,E). This clearly
indicates a T cell-intrinsic role for MALT1 protease activity in
nTreg development.
Tregs are present in the cLN of young Malt1-PD and -PDT
mice, albeit at lower levels than in control mice (Figures 4C,D).
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FIGURE 4 | Reduced Treg frequency and reduced surface CTLA-4 expression
on Tregs and effector CD4+ T cells in Malt1-PD and Malt1-PDT mice. (A,B)
Treg frequency (Foxp3+CD25+CD4+CD8− T cells) in thymus of young
Malt1-PD (n = 6) (A) and Malt-PDT (n = 3) (B) mice and their corresponding
controls (n = 5 and n = 3, respectively). (C,D) Treg frequency in cLN of young
Malt1-PD (n = 6) (C) and Malt1-PDT (n = 3) (D) mice and their corresponding
controls (n = 5 and n = 3, respectively). (E,F) Treg frequency in Malt1-PD (n =
11) (E) and Malt1-PDT (n = 6) (F) mice suffering from ataxia and their
corresponding controls (n = 12 and n = 9, respectively). Lymphocytes were
stimulated for 4 h with PMA/ionomycin and the data represent three individual
experiments: experiment 1 = filled squares, experiment 2 = open squares and
experiment 3 = open circles. (G,H) Normalized CTLA-4 expression on the
surface of Tregs (G) and CD44+CD4+ T cells (H) from young disease free
Malt1-PDT mice (n = 15) and their corresponding controls (n = 15).
(Continued)
FIGURE 4 | The individual percentages of Foxp3+CD4+ T cells or
CD44+CD4+ T cells that express CTLA-4 on their surface is normalized
against the average percentage of the corresponding control mice of each
individual experiment. Lymphocytes were stimulated for 4 h with
PMA/ionomycin and data represent two individual experiments: experiment 1
= filled squares, experiment 2 = open squares. For (A–H): all data were
obtained via flow cytometry. The mean ± SEM is indicated on the graphs. The
statistical significance between groups was calculated with an unpaired 2
tailed Student’s t-test: *p < 0.05, **p < 0.01, ***p < 0.001, and
****p < 0.0001.
FIGURE 5 | Bregs are almost absent in Malt1-PD mice, but are present in
Malt1-PDT mice. IL-10 secretion by control (n = 4), Malt1-PD (n = 3), and
Malt1-PDT (n = 3) splenic B cells after overnight stimulation with TLR9 ligand
CpG. The mean ± SEM is indicated on the graphs. The statistical significance
between groups was calculated with an unpaired 2 tailed Student’s t-test:
*p < 0.05 and **p < 0.01.
The higher Treg numbers found in cLN of young Malt1-
PDT mice could be a secondary effect from inflammation-
induced formation of iTregs or peripheral proliferation of the few
remaining nTregs. The nearly absent levels of Tregs in thymus,
but detectable levels of Tregs in the periphery is a common
feature of Malt1-PD and -PDT mice, as well as Malt1-KO
mice (4, 5, 47, 54, 56).
In addition to a decrease in Tregs, also a decrease in the
amount of Bregs was suggested to contribute to the autoimmune
disease phenotype in Malt1-PD mice (47). Bregs can originate
from many different B cell lineages, where marginal zone
(MZ) B cells serve as an important source in the spleen
(57). MZ B cells are disrupted in Malt1-KO and Malt1-PD
mice. We therefore investigated MZ B cell development in
T cell-specific Malt1-KO and Malt1-PDT mice compared to
WT and full-body Malt1-PD and -KO mice. In contrast to
full body Malt1-PD and -KO mice, MZ B cell development
is completely normal in both T cell-specific Malt1-KO and
Malt1-PDT mice (Supplemental Figures 2A–D). Furthermore,
in contrast toMalt1-PDmice, Bregs were not absent in theMalt1-
PDT mice (Figure 5). Together, these findings argue against a
contribution from a decrease in IL-10 producing Bregs to the
autoimmune phenotype.
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Loss of MALT1 Proteolytic Activity
Reduces Expression of the Treg
Functionality Marker CTLA-4
Previously Jaworski et al. (4) and Bornancin et al. (47) reported
a reduction of peripheral Tregs in Malt1-PD mice. We could
confirm this in cLN from young disease-freeMalt1-PD mice and
in mice already suffering from ataxia. Notably, at the time of
sacrifice, when the mice had developed ataxia, the number of
peripheral Tregs in Malt1-PDT mice is higher than in Malt1-
PD mice (Figures 4E,F), indicating that also MALT1 protease-
dependent signals from non-T cells may promote peripheral
Treg induction. Nevertheless, both Malt1-PD and -PDT mice
developed equally severe disease symptoms, indicating that
disease development in the Malt1-PD and -PDT cannot be
solely explained by reduced peripheral iTreg levels. Therefore,
we assessed the functionality of Tregs by means of their surface
expression of CTLA-4, which binds CD80 and CD86 proteins
found on the surface of antigen presenting cells. These proteins
provide, by binding to CD28 on the T cells, the costimulatory
signal needed for optimal T cell activation. By expressing
CTLA-4, Tregs can downregulate CD80 and CD86 expression on
antigen presenting cells, leading to reduced T cell proliferation,
survival and IL-2 production (58). We have previously observed,
via flow cytometry on splenocytes, that the percentage of
Foxp3+CD4+ T cells that express CTLA-4 on their surface is
reduced in Malt1-KO mice compared to WT mice (unpublished
data). To assess the effect of MALT1 proteolytic activity on the
percentage of Tregs (Foxp3+CD4+ T cells) with surface CTLA-
4 expression, we isolated cells from cLN of young disease-free
Malt1-PDT mice and analyzed CTLA-4 surface expression by
flow cytometry. This revealed that the percentage of surface
CTLA-4 expressing Tregs was also reduced in Malt1-PDT mice
compared to control mice (Figure 4G). The reduced expression
of CTLA-4 is not the result of a generalized defect in effector Treg
differentiation, since expression of other Treg effector markers is
not affected (Supplemental Figures 3A–D). CTLA-4 can also be
expressed on effector CD4+ T cells (CD44+CD4+ T cells), where
reduced expression is associated with elevated tissue infiltration
and suppression of autoreactivity (59, 60). As for the Tregs, also
here the percentage of CTLA-4 surface-positive CD44+CD4+ T
cells was found to be reduced in young disease-free Malt1-PDT
mice (Figure 4H). Together, these results clearly demonstrate
that MALT1 proteolytic activity in T cells regulates CTLA-4
surface expression in Tregs and CD44+CD4+ T cells, indicating
that MALT1 proteolytic activity influences Treg functionality in a
T cell-intrinsic manner, since even amoderate decrease in CTLA-
4 expression can lead to autoimmunity in humans (61). The
reduced CTLA-4 expression could thus be an important factor
regulating autoimmunity in theMalt1-PDT mice.
T Cell-Specific Transgenic Human MALT1
Reconstitution Rescues MALT1
Protease-Deficient Mice From
Autoimmune Disease
Since both full-body Malt1PD/− and T cell-specific Malt1PD/FL
CD4-Cre mice equally develop an inflammatory phenotype,
we can conclude that the loss of MALT1 proteolytic activity
in cells targeted by CD4-Cre is sufficient to induce a full
autoimmune response. To verify that MALT1 enzymatic activity
in other cells not targeted by CD4-Cre may still contribute
to the development of autoimmune disease, we generated
Malt1PD/− Rosa26LSL-MALT1-WT CD4-Cre mice in which all cells
endogenously express protease-dead MALT1, and where human
WT MALT1 is specifically expressed as a transgene in cells
that have experienced CD4-Cre activity. These mice did no
longer show gastritis and immune infiltration in lacrimal and
salivary glands as observed inMalt-PD mice (Figures 6A,B), nor
did they show an increase in IFN-γ producing CD4+ T cells
(Figure 6C). Moreover, transgenic expression of WT MALT1 in
cells targeted by CD4-Cre in aMalt1-PD background suppressed
the strong drop in the amount of Tregs in the thymus and
cLN of Malt1-PD mice (Figures 6D,E). The complete rescue of
the autoimmune phenotype in full-body Malt1-PD mice by T
cell-specific WT MALT1 expression further demonstrates that
only T cell MALT1 protease activity is critical to suppress the
autoimmune phenotype.
DISCUSSION
MALT1 proteolytic activity plays a key role in both immune
cells and non-immune cells (62, 63), and mice expressing a
catalytically inactive MALT1 mutant (Malt1-PD mice) were
previously shown to suffer from severe autoimmunity (4–6, 47).
Conditional genetic models are essential to determine the
critical cell type responsible for disease development in
Malt1-PD mice. We studied the T cell-intrinsic functions of
MALT1 proteolytic activity in the regulation of immune and
autoimmune responses by comparing Malt1-PD mice with
Malt1-PDT mice that specifically express catalytically inactive
MALT1 in T cells. We report that both lines develop similar
disease symptoms and autoimmunity, indicating that MALT1
proteolytic activity suppresses autoimmunity in a T cell-
intrinsic manner. Autoimmune disease in Malt1-PD mice was
previously explained by a disrupted balance between effector
CD4+ T cells and the number of Tregs (4, 5, 47). Both
Malt1-PD and Malt1-PDT mice have almost no nTregs in
their thymus, indicating a T cell-intrinsic role of MALT1
protease activity in thymic Treg development. nTregs inhibit
autoreactive T cells to become mature Th1 cells (53, 64). If
induced peripheral Tregs cannot compensate for the lack of
thymus-derived nTregs, this may explain the Th1-dependent
autoimmune phenotype of Malt1-PD and Malt1-PDT mice.
Therefore, it might be interesting to investigate whether inducible
genetic inactivation of MALT1 proteolytic activity in adult
animals results in a similar phenotype. Moreover, less well-
known Foxp3-negative regulatory T cell populations (e.g., Tr1
and Th3 cells) (52) may also play a role. Of note, the
reduction of Foxp3+ Tregs is less pronounced in Malt1-
PDT mice compared to Malt1-PD mice, suggesting that also
MALT1 protease-dependent signals from cells not targeted by
CD4-Cre contribute to the decrease in Tregs. One non-T cell
population that could influence Treg numbers and which is
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FIGURE 6 | Expression of hMALT1 in T cells of Malt1-PD mice rescues the disease phenotype. (A,B) H&E staining of stomach (A) and salivary gland (B) of Malt1-PD
(PD) and Malt1-PD mice expressing wild type human MALT1 in T cells (Malt1PD/- Rosa26LSL-MALT1-WT CD4-Cre = PD hWT-T) mice. (C) Percentage of
CD44+CD4+ T cells producing IFN-γ in PD and PD hWT-T mice. (D) Treg frequency (Foxp3+CD25+CD4+CD8− T cells) in thymus of PD and PD hWT-T mice.
(E) Treg frequency in cLN of PD and PD hWT-T mice. For (C–E): all data were obtained via flow cytometry and for (E), lymphocytes were stimulated for 4 h with
PMA/ionomycin. Data represent two individual experiments: experiment 1 = open squares and experiment 2 = filled squares. Malt1-PD mice: total n = 7 and
Malt1-PD hWT-T mice: total n = 5, age 13–18 weeks. The mean ± SEM is indicated on the graphs. The statistical significance between groups was calculated with
an unpaired 2 tailed Student’s t-test: *p < 0.05 and ****p < 0.0001.
different between Malt1-PD and Malt1-PDT mice are the Breg
cells (65, 66).
As Malt1-PD and Malt1-PDT mice develop equally severe
disease symptoms, disease development cannot be solely
explained by reduced peripheral Treg levels. Therefore, we also
assessed the Treg surface expression of CTLA-4, which is a known
Treg functionality marker and whose deficiency partially leads
to similar disease symptoms as those seen in Malt1-PD and -
PDT mice (64, 67–70). In addition, in vivo models for colitis
and diabetes demonstrate the importance of CTLA-4 for the
Treg inhibitory function (69). It is believed that the inhibitory
effect of Tregs occurs via CTLA-4 mediated trans-endocytosis
of CD80 and CD86 proteins from antigen presenting cells (71),
which impairs CD28 co-stimulation that is required for optimal
T cell activation (58, 71). We found that the number of Tregs that
expressed CTLA-4 on their surface was much lower in Malt1-
PDT mice compared to WT controls. We therefore propose that
not the reduced number of Treg per se, but rather impaired Treg
functionality is responsible for autoimmune disease development
in Malt1-PDT mice. Of note, also the number of effector CD4+
T cells expressing CTLA-4 on their surface was found to be
reduced in Malt1-PDT mice compared to controls. CTLA-4 on
effector CD4+ T cells can also inhibit T cell responses in a
cell extrinsic way, but their suppressive capacities are modest
compared to Tregs (72, 73). Nevertheless, reduced CTLA-4
expression on effector CD4+ T cells might also contribute
to the disease phenotype observed in our Malt1-PD and
-PDT mice.
CTLA-4 expression on T cells depends onmTORC1 activation
downstream of TCR stimulation (74). Of interest, mTORC1
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activation was recently shown to requireMALT1 protease activity
via regulation of the glutamine import protein ASCT2 (75, 76).
Reduced CTLA-4 expression on Tregs and effector CD4+ T
cells from Malt1-PDT mice might therefore reflect reduced
mTORC1 activation. Moreover, since CTLA-4 mRNA is directly
targeted for degradation by the MALT1 substrates Regnase-
1, Roquin-1, and Roquin-2 (37), reduced CTLA-4 expression
on Tregs and effector CD4+ T cells from Malt1-PDT mice
may also reflect its post-transcriptional regulation by MALT1.
Based on our results, we propose that future risk assessments
of MALT1 protease inhibition related to autoimmunity could
focus on the effect of MALT1 inhibitors on Treg differentiation,
maintenance and functionality. It should be mentioned that there
is an important difference between genetic and pharmacological
approaches to assess the role of MALT1 proteolytic activity in
immune homeostasis. In case of genetic inactivation, MALT1
function is disrupted already in the germline (in case of full-
body KI mice) or is removed during early T cell differentiation
(in case of conditional CD4-Cre KI mice). In contrast, upon
pharmacological inhibition with for example small compound
inhibitors of MALT1, Tregs are MALT1 protease proficient
before the treatment is started, which may result in a different
outcome. While the current paper was written, however, several
studies using Malt1FL/PD Foxp3-CreTg/+ mice that specifically
express catalytically inactive MALT1 in Tregs indicated that
post-development loss of MALT1 proteolytic activity in Tregs
leads to severe autoimmune disease (77–79), which might raise
concerns regarding the safety of pharmacological inhibition
of MALT1 protease activity. Based on our results on CTLA-
4 and the above mentioned other studies, it would be highly
interesting to see whether Foxp3-Cre conditional KO of Regnase-
1 and/or Roquin-1 and Roquin-2 can rescue the autoimmune
disease in Malt1-PD mice. Noteworthy, a MALT1 protease
inhibitor will dampen both effector T cells and Tregs, which
can still lead to a different immune homeostasis phenotype
compared to the autoimmune phenotype upon Treg-specific
loss of MALT1 proteolytic activity. Importantly, there is already
indirect evidence indicating that therapeutic targeting of MALT1
protease activity in adult mice with small compound inhibitors
is safe. Firstly, extended treatment of mice with the MALT1
protease inhibitor mepazine did not reduce Treg numbers (40).
As a counterexample, long-term treatment of psychiatric patients
with chlorpromazine, another MALT1 inhibitor, is associated
with the induction of autoimmunity markers and occasionally
results in a lupus-like disease (80, 81). It is however important
to stress that both these phenothiazine compounds also have
other MALT1-independent activities that can be responsible for
the observed effects (82). Another argument in favor of safety
for MALT1 inhibitor treatment in adults is the fact that MALT1
seems to be specifically required for the development of nTregs,
which develop at a young age in the thymus (54). A third
compelling argument is that only a small amount of functional
(WT) Tregs is enough to suppress the autoimmune phenotype
of Malt1-PD mice (5). Since therapeutic inhibition of enzymatic
activity is never complete and can be adjusted by dosage and
treatment regimes, it might be that the remaining functional
Tregs are enough to prevent autoimmunity. Nevertheless, a
major future challenge will be to generate and characterize
inducible genetic models to emulate the effects of long-term
inhibitor treatment in adults.
MATERIALS AND METHODS
Mouse Rosa26LSL-hMALT1-WT Transgenesis
Cloning of RMCE-Targeting Constructs
Plasmids of the cloned genes were deposited in the
BCCM/GeneCorner plasmid collection along with detailed
descriptions of cloning strategy and plasmid sequence (http://
www.genecorner.ugent.be/). Human MALT1 (LMBP 9104,
LMBP 9105) was cloned into pENTR221 together with a
genotype-specific barcode sequence downstream of the stop
codon for genotyping. The ENTR clones were integrated in
the pRMCE_DV1 (LMBP 8870) destination vector to generate
RMCE targeting vectors forMALT1 (LMBP 9111, LMBP 9112).
RMCE Targeting
RMCE compatible mouse ES-cells [G4 ROSALUC (83)] were
cultured in standard ES-cell medium containing 500ml KO-
DMEM (Thermo Fisher Scientific), 15% serum (Hyclone),
100µMNon-essential amino acids (Thermo Fisher Scientific), 1x
Glutamax (Thermo Fisher Scientific), 100µM β-mercaptothanol
(Thermo Fisher Scientific) and 2,000 units LIF/ml (VIB Protein
Core). ES-cells were co-transfected with 2.5 µg of a FlpE
expressing plasmid (84) and 2.5 µg of targeting vector using
lipofectamin 2000 (Thermo Fisher Scientific) according to the
manufacturer’s instructions. G418 selection (200µg/ml) was
applied 48 h after transfection. After 7–10 days, individual G418
resistant, RMCE targeted ES cell clones were picked and further
expanded. Correct targeting events were confirmed by Southern
blot analysis (5
′
probe, EcoRI, wt = 15,5 kb/mutant = 4.5
kb/wtRosaluc allele = 6 kb; EGFP internal probe, KpnI, single
integration = 11 kb) and by PCR; the targeted allele generates
a band of 560 bp (primers: FW 5
′
AAA GTC GCT CTG AGT
TGT TAT 3
′
and REV 5
′
GCG GCC TCG ACT CTA CGA
TA 3
′
). Correctly targeted ES-cells were aggregated with outbred
Swiss morula, which were then implanted into pseudopregnant
Swiss mice.
Mice
In order to generate conditional Malt1-KO mice, mice were
generated from the EUCOMM Malt1tm1a(EUCOMM)Hmgu/+ ES
cells (85), which were back-crossed to a germ line Flp
deleter (86) to generate Malt1FL/+ mice. These mice were
further crossed to the CD4-Cre (87) line and back-crossed to
generate Flp-negative T cell-specificMalt1-KO (Malt1FL/FL CD4-
Cre) (88–91). The Malt1tm1a(EUCOMM)Hmgu/+ mice were also
back-crossed with a germline Cre-line and back crossed to
generate Cre-negative co-isogenic Malt1−LacZ/−LacZ full-body
KO mice. Malt1PD/+ (the mouse MALT1 C472A mutation that
disrupts protease activity) mice were generated in a C57/BL6
background by CRISPR/Cas9 (92) by Cyagen Biosciences
Inc. Malt1-PD mice were always maintained as heterozygotes
(Malt1PD/+) in breeding to avoid suffering from the autoimmune
phenotype. Rosa26LSL-MALT1-WT transgenic mice were crossed
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with CD4-Cre and subsequently back-crossed with full-body
Malt1 KO mice, and later back-crossed to Malt1PD/+ mice to
generate rescuedMalt1PD/− Rosa26LSL−MALT1−WT CD4-Cre and
Malt1PD/PD Rosa26LSL−MALT1−WT CD4-Cre mice where all cells
except T cells are MALT1 protease deficient. The transgenes
were confirmed by western blot (Supplemental Figure 4) for
specific expression of MALT1 only in presence of CD4-Cre
using a human-specific rabbit monoclonal anti-MALT1 antibody
(EP603Y, Abcam), anti-mouse MALT1 (sc-28246, Santa Cruz)
and anti-Cre (69050-3, Merck Millipore). Mice used in these
experiments were kept at room temperature, fed ad libitum in
an SPF facility (IRC, VIB-UGent). All experiments were done
according to the UGent ethical guidelines with the local ethical
committee approval number: EC 2015-031.
Genotyping
TheMalt1 Flox-allele or KO allele from Eucomm was monitored
with the primers MALTcKO-F (GTTTCTCAGGTCTTTA
GTTCATGTC), CoMLT-3-R (TATACTCTACATCTCCAT
GGT), MALTcKO-R (TTGTTTTGCAGATCTCTGCC), and
MLT-LacZ-F (TCGCTACCATTACCAGTTGGT) resulting
in 280 bp (WT), 400 bp (FL), 345 (KO), or 514 bp (KO-
LacZ) PCR products. SNP-specific primers were designed as
described in Staal et al. (93), with the allele-specific nucleotides
close to the 3
′
end of the primer. The Malt1 C472A KI was
monitored with the primers F-MALT-KICA-GT (CCCA
CTCCCAGGATTGTTATATT), R-MALT1-KICA-GT (TGCT
CTAGATCCACAGGTGTGGTT), KI-MALT-CA-F (AATG
TGTTCCTGTTGGATATGGCCAG), and KI-MALT-WT-R
(GAGACATTTTACCTTTTCCGACAC) resulting in 461
bp (allele-independent), 304 bp (PD) and 201 bp (WT)
PCR fragments. The Rosa26LSL-MALT1-WT transgenes were
genotyped with the primers RMCE-MALT-F (GCAGCTAC
TTGGTATCAAAGGATCT), RMCE-MALT-R (TTTCCACAA
CTATCCATGTCGC), generating an allele-independent 896
bp PCR fragment, and the allele-specific primer RMCE-
MALT-WT-R (CCAATTTCTGAAAAATAGTGTCCAAC)
generating an allele specific band of 537 bp. Flp was detected
with the primers Flp-F (TTAGTTCAGCAGCACATGATG)
and Flp-R (GGAGGATTTGATATTCACCTG), resulting in
a 370 bp PCR fragment. Cre was detected with the primers
Cre-F (TGCCACGACCAAGTGACAGCAATG) and Cre-R
(AGAGACGGAAATCCATCGCTCG) producing a 374 bp PCR
fragment. All genotypings were done using the GoTaq Green Hot
Start (Promega) master mix, with a typical PCR program: 5min
95◦C denaturation, 35–40 cycles [30 s 95◦C|30 s 52–60◦C|60 s
72◦C] and 10min 72◦C final elongation.
Flow Cytometry
Data were obtained with a LSRII flow cytometer (BDBiosciences)
and FlowJo Software (Treestar, Inc., Ashland, Ore) was used for
data analysis.
Detection of Tregs
Cells from thymus and cLN were surfaced stained with
Fixable Viability Dye eFluor506 (eBioscience), anti-CD16/CD32
Fc block (clone 2.4G2; BD Biosciences), anti-CD3-eFluor450
(clone 17A2; eBioscience), anti-CD4-FITC (clone GK1.5; BD
Biosciences or eBioscience), anti-CD25-PercPcy5.5 (clone PC61;
BD Biosciences) for 20min. Next, cells were permeabilized for
30min, followed by 30min of intracellular staining for anti-
Foxp3-PE (clone FJK-16s; eBioscience). For the intracellular
staining, the Foxp3 buffer set (eBioscience) was used and all
incubation steps were done on ice.
Analysis of Effector Markers on Tregs
Cells from cLN cultured in complete medium (RPMI 1640
medium supplemented with 10% FCS, sodium pyruvate,
L-glutamine, antibiotics and β-mercaptoethanol) were
stimulated with PMA (50 ng/ml) and ionomycin (1µg/ml)
for 4 h at 37◦C. The cells were stained as mentioned above,
but anti-CD44-APC-efluor780 (clone IM7; eBioscience) and
anti-CTLA-4 PE-eFluor610 (clone UC10-4B9; eBioscience)
were also included in the surface staining. For the other Treg
effector markers, non-stimulated cells from cLN were stained
as mentioned above, but anti-CD44-AlexaFluor700 (clone
IM7; BD Pharmingen), anti-CD62L-eFluor450 (clone MEL-14;
eBioscience) and anti-KLRG1-APC (clone 2F1; eBioscience)
or anti-TNFR2-BV421 (clone TR75-89; BD Pharmingen) and
anti-ICOS-PE-Cy5 (clone 7E.17G9; eBioscience) were also
included in the surface stain.
Analysis of Cytokines by Intracellular Cytokine
Staining
Cells from cLN were cultured in complete medium and
stimulated with PMA (50 ng/ml), ionomycin (500 ng/ml) and
brefeldin A (1µg/ml) for 4–5 h at 37◦C. Stimulated cells were
washed, surface stained with anti-CD16/CD32, Fixable Viability
Dye eFluor 506, anti-CD3-eFluor450, anti-CD4-FITC, anti-
CD44-APCeFluor780, for 20min. Next, cells were fixed and
permeabilized for 30min using the Foxp3 buffer set, followed
by intracellular staining with anti-IFNγ-PE-Cy7 (clone XMG1.2;
BD Pharmingen) for 30 min.
Detection of MZ B Cells
Spleen cells were surface stained with Fixable Viability Dye
eFluor506 (eBioscience), anti-CD16/CD32 Fc block (clone
2.4G2; BD Biosciences), anti-CD3-PE-Cy5 (145-2C11;
Tonbo Biosciences), anti-CD45R/B220 (clone RA3-6B2;
BD Biosciences), anti-CD21/CD35-eFluor450 (clone 4E3;
eBioscience), and anti-CD23-PE-Cy7 (clone B3B4,eBioscience)
for 20 min.
Cytokine Analysis
Peripheral blood samples were collected for serum preparation.
The levels of IL-2 (171-G5003M), IL-4 (171-G5005M), IL-
6 (171-G5007M), IL-17 (171-G5013M), IFN-γ (171-G5017M),
and TNF (171-G5023M) were determined by Bio-Plex (Biorad)
according to the manufacturer’s conditions. B cells were purified
from spleen with the MagniSort Mouse B cell Enrichment
Kit (eBioscience), cultured in complete medium (RPMI 1640
medium supplemented with 10% FCS, sodium pyruvate,
L-glutamine, antibiotics and β-mercaptoethanol) and stimulated
overnight with 20µM CpG1826 (Invivogen) as described (47).
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The level of IL-10 (171G5009M) in medium was determined by
Bio-Plex (Biorad) according to manufacturer’s conditions.
Histology
Stomach, lacrimal gland and salivary gland were fixed with 4%
paraformaldehyde and imbedded in paraffin. Sections (5µm)
were stained with haematoxylin and eosin. Images (100×
magnification) were acquired with a BX51 discussionmicroscope
(Olympus) with PixeLink camera under 100×magnification.
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